News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

May 30, 2013
London, UK, 30 May 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics
May 14, 2013
London, UK, 14 May 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics
May 08, 2013
London, UK, 8 May 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics
May 07, 2013
London, UK, 7 May 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics
May 01, 2013
- GW announced today the pricing of its initial public offering of 3,500,000 American Depository Shares (“ADSs”) on the NASDAQ Global Market at a price of $8.90 per ADS -
Apr 22, 2013
- Follows Recent Notice of Allowance for Sublingual Delivery of Sativex Formulation Patent-
Apr 18, 2013
Porton Down, UK, 18 April 2013: GW Pharmaceuticals plc (AIM: GWP or the “Company”) hereby provides notification that, further to the announcement on 19 March 2013 of the filing of a registration sta
Apr 12, 2013
Porton Down, UK, 12 April 2013: GW Pharmaceuticals plc (AIM: GWP or the “Company”) hereby provides notification that, at the General Meeting of Company held earlier today, all the resolutions set ou
Apr 10, 2013
- Legal step lessens restrictions, recognises low potential for abuse & low risk of diversion -
Apr 03, 2013
Porton Down, UK; 3 April 2013: GW Pharmaceuticals plc (AIM: GWP), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabino

Pages